SHR-1901 / Jiangsu Hengrui Pharma - LARVOL DELTA

A Clinical Study of the Safety and Tolerability of SHR-1901 in Subjects With Advanced Malignant Tumors (clinicaltrials.gov) - P1 | N=25 | Active, not recruiting | Sponsor: Suzhou Suncadia Biopharmaceuticals Co., Ltd. | Recruiting ➔ Active, not recruiting | N=180 ➔ 25

Enrollment change • Enrollment closed • Metastases • Gastrointestinal Cancer • Oncology • Solid Tumor